Satsuma Pharmaceuticals Announces Poster Presentations on the American Academy of Neurology 2020 Science Highlights Virtual Platform

           Pharmacokinetic comparison of STS101, an intranasal dry powder formulation of dihydroergotamine, with other intranasal, injectable and oral inhaled DHE formulations

 Water-insoluble Mucoadhesive Formulation Enables Consistent and Rapid Intranasal Absorption of Drugs, including Granisetron, Zolmitriptan and Dihydroergotamine  

SOUTH SAN FRANCISCO, Calif., May 18, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that two abstracts and scientific presentations from its STS101 (dihydroergotamine (DHE) nasal powder) development program for the acute treatment of migraine were selected for presentation on the 2020 American Academy of Neurology (AAN) Annual Meeting Science Highlights Virtual Platform.  The 2020 AAN Science Highlights Virtual Platform will go online on May 18 and replaces the AAN 72^nd annual meeting previously scheduled for April 25–May 1. The abstracts were also published in the online supplement to the journal Neurology and presentations will be available for download at 4pm Eastern Time on Monday, May 18, 2020 in the Publications section of Satsuma's website:  https://www.satsumarx.com/publications/.

Poster:	P14.006
Title:	Water-insoluble Mucoadhesive Formulation Enables Consistent and Rapid Intranasal Absorption of Drugs, including Granisetron, Zolmitriptan and Dihydroergotamine
Presenter:	Mic Iwashima
Poster:	P14.008
Title:	PK Comparison of STS101, an Intranasal Dry Powder Formulation of Dihydroergotamine, with Other Intranasal, Injectable and Oral Inhaled DHE Formulations
Presenters:	Shannon  Strom, PhD
	Detlef Albrecht, MD
	John Kollins

About Satsuma Pharmaceuticals and STS101

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product for the acute treatment of migraine, STS101. STS101 is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate (DHE), which can be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. In developing STS101, Satsuma has applied proprietary nasal drug delivery, dry-powder formulation, and engineered drug particle technologies to create a compact, simple-to-use, non-injectable DHE product that can be rapidly self-administered in a matter of seconds. The Company believes STS101 would, if approved, be an attractive migraine treatment option for many patients and may enable a larger number of people with migraine to realize the long-recognized therapeutic benefits of DHE therapy. STS101 has undergone extensive pre-clinical development, completed a Phase 1 clinical trial, and is currently in Phase 3 development.